Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 349 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bupropion HCl Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

NCT00504413
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
midazolam(drug), digoxin (drug), Bupropion (drug), Methadone (drug)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

Mechanistic Evaluation of Response in TRD (MERIT)

NCT04608396
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Maintenance Treatment for Abstinent Smokers

NCT00063323
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 75 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

NCT02735603
View directory record Official record
Conditions
Heart Repolarization
Interventions
Naltrexone HCl/bupropion HCl, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Not applicable Interventional

A Feasibility Study of Smoking Cessation Program in Radiation Oncology

NCT00236288
View directory record Official record
Conditions
Cancer and Tobacco Abuse
Interventions
Bupropion and intensive behavioral therapy
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 30, 2007 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

NCT02259179
View directory record Official record
Conditions
Healthy
Interventions
Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Integrated Treatment for Cocaine and Mood Disorders - 1

NCT00227812
View directory record Official record
Conditions
Cocaine Dependence, Depressive Disorder, Major
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 4, 2026, 5:05 AM EDT
Recruiting Phase 4 Interventional

Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities

NCT06997198
View directory record Official record
Conditions
Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions
Deutetrabenazine Oral Capsule
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2

NCT00135785
View directory record Official record
Conditions
Methamphetamine
Interventions
Bupropion, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 100 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
Los Angeles, California • Rancho Cucamonga, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

NCT01838876
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
88
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

NCT00711477
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, fMRI scan
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Upton, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

NCT03199339
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBA-7371, Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

NCT01806779
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Chantix, Zyban, Nicotine patches
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 3 Interventional

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

NCT04797715
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
61
States / cities
Sun City, Arizona • Tucson, Arizona • Chula Vista, California + 55 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 3 Interventional

Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression

NCT00179244
View directory record Official record
Conditions
Unipolar Depression
Interventions
Rispridone (drug) and Bupropion ER (drug)
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Maintenance Treatment for Smoking Cessation

NCT01615770
View directory record Official record
Conditions
Smoking
Interventions
cognitive behavior therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Bupropion SR for Treating Smokeless Tobacco Use

NCT00414180
View directory record Official record
Conditions
Smokeless Tobacco
Interventions
Bupropion SR
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

NCT06679413
View directory record Official record
Conditions
Healthy Study Participants
Interventions
midazolam, metformin, bupropion, fenfluramine HCl
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers

NCT01714323
View directory record Official record
Conditions
Cigarette Smoking, Tobacco Smoking, Tobacco Use Disorder
Interventions
Sustained Care, Standard Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Salem, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals

NCT00249509
View directory record Official record
Conditions
Marijuana Abuse
Interventions
Nefazodone, Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 2Phase 3 Interventional

Female Orgasmic Disorder (FOD) and Wellbutrin XL

NCT00248209
View directory record Official record
Conditions
Orgasmic Disorder
Interventions
Wellbutrin XL
Drug
Lead sponsor
Segraves, R., T., M.D., Ph.D.
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Adaptive Pharmacotherapy for Smoking Cessation

NCT02501265
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline Standard Protocol, Nicotine Patch Standard Protocol, Varenicline Adaptive Protocol, Nicotine Adaptive Protocol
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Not applicable Interventional Results available

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

NCT00129467
View directory record Official record
Conditions
Depression, Palliative Care, Cancer, Mental Disorder
Interventions
Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 4, 2026, 5:05 AM EDT
Completed Not applicable Interventional Results available

Bupropion in the Treatment of Methamphetamine Dependence

NCT00572234
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
bupropion SR
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 4, 2026, 5:05 AM EDT